Literature DB >> 16432628

Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain.

N David Aberg1, Katarina Gustafson Brywe, Jörgen Isgaard.   

Abstract

Apart from regulating somatic growth and metabolic processes, accumulating evidence suggests that the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis is involved in the regulation of brain growth, development, and myelination. In addition, both GH and IGF-I affect cognition and biochemistry in the adult brain. Some of the effects of GH are attributable to circulating IGF-I, while others may be due to IGF-I produced locally within the brain. Some of the shared effects in common to GH and IGF-I may also be explained by cross-talk between the GH and IGF-I transduction pathways, as indicated by recent data from other cell systems. Otherwise, it also seems that GH may act directly without involving IGF-I (either circulating or locally). Plasticity in the central nervous system (CNS) may be viewed as changes in the functional interplay between the major cell types, neurons, astrocytes, and oligodendrocytes. GH and IGF-I affect all three of these cell types in several ways. Apart from the neuroprotective effects of GH and IGF-I posited in different experimental models of CNS injury, IGF-I has been found to increase progenitor cell proliferation and new neurons, oligodendrocytes, and blood vessels in the dentate gyrus of the hippocampus. It appears that the MAPK signaling pathway is required for IGF-I-stimulated proliferation in vitro, whereas the PI3K/Akt or MAPK/Erk signaling pathway appears to mediate antiapoptotic effects. The increase of IGF-I on endothelial cell phenotype may explain the increase in cerebral arteriole density observed after GH treatment. The functional role of GH and IGF-I in the adult brain will be reviewed with reference to neurotransmitters, glucose metabolism, cerebral blood flow, gap junctional communication, dendritic arborization, exercise, enriched environment, depression, learning, memory, and aging. Briefly, these findings suggest that IGF-I functions as a putative regenerative agent in the adult CNS. Hitherto less studied regarding in these aspects, GH may have similar effects, especially as it is the main regulator of IGF-I in vivo. Some of the positive cognitive features of GH treatment are likely attributable to the mechanisms reviewed here.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432628      PMCID: PMC5917186          DOI: 10.1100/tsw.2006.22

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  116 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease.

Authors:  Miguel Agustin Contreras; William Louis Ries; Srinivasan Shanmugarajan; Gonzalo Arboleda; Inderjit Singh; Avtar Kaur Singh
Journal:  Biochim Biophys Acta       Date:  2010-05-02

Review 3.  Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches.

Authors:  Daniel Garzón; Ricardo Cabezas; Nelson Vega; Marcos Ávila-Rodriguez; Janneth Gonzalez; Rosa Margarita Gómez; Valentina Echeverria; Gjumrakch Aliev; George E Barreto
Journal:  J Mol Neurosci       Date:  2016-01-23       Impact factor: 3.444

Review 4.  Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline.

Authors:  Karyn M Frick
Journal:  Behav Neurosci       Date:  2012-02       Impact factor: 1.912

Review 5.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

6.  Impairment of GH secretion in amyotrophic lateral sclerosis is not affected by riluzole treatment.

Authors:  L L Morselli; P Bongioanni; M Genovesi; R Licitra; B Rossi; L Murri; F Bogazzi; E Cecconi; E Martino; M Gasperi
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

7.  The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging.

Authors:  Alexandra M V Wennberg; Clinton E Hagen; Mary M Machulda; John H Hollman; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Michelle M Mielke
Journal:  Neurobiol Aging       Date:  2018-02-19       Impact factor: 4.673

Review 8.  Somatotropic signaling: trade-offs between growth, reproductive development, and longevity.

Authors:  Andrzej Bartke; Liou Y Sun; Valter Longo
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

9.  Neuroprotective effects of IGF-I following kainic acid-induced hippocampal degeneration in the rat.

Authors:  Panagiota Miltiadous; Antonios Stamatakis; Fotini Stylianopoulou
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

Review 10.  Exercise and brain health--implications for multiple sclerosis: Part 1--neuronal growth factors.

Authors:  Lesley J White; Vanessa Castellano
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.